CAR exosomes isolated from CAR-T cells loaded with cetuximab or trastuzumab scFv, respectively target and treat EGFR- or HER-2-positive breast and ovarian cancer [263]. This evidence concerns the gene ERBB2 and ovarian carcinoma.